[email protected]
  1. Home
  2. Pharmaceuticals
  3. 040-000-296 Ritonavir, CAS 155213-67-5

040-000-296 Ritonavir, CAS 155213-67-5

ritonavir
SKU: 040-000-296 Category:
Get A Quote






  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Synonym Norvir
Type Antibiotics, protease, tyrosine kinase inhibitor
Keywords COVID-19, HIV, antiviral, AIDS, SARS-CoV-2
Related products Piperaquine, Chloroquine Diphosphate, Artemisinin, Acrichin Dihydrochloride
Description

Description

Ritonavir Specifications

Product Name Ritonavir
CAS Registry Number 155213-67-5
Molecular Formula C37H48N6O5S2
Molecular Weight 720.946 g/mol
Purity 98%
Appearance White powder
Package 1kg-25kg
Shelf life 2 years
Functions Antiviral, therapy for HIV-1, potential inhibitor of COVID-19

Ritonavir Description

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. The mechanism of action of the anti-HIV drug lopinavir and ritonavir is to block the enzymes required for virus replication. It is often used in combination with other antiretrovirals and serves as both a protease inhibitor and a pharmacokinetic enhancer. Lopinavir/ritonavir have been shown to reduce coronavirus levels that cause SARS and MERS in animal studies.

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.

ritonavir

ritonavir

Ritonavir Solubility / Properties

Ritonavir is poorly soluble in water, with solubility less than 1 mg/mL at physiological pH. This poor solubility can impact its bioavailability and absorption in the body, necessitating the use of formulations that enhance its solubility for effective therapeutic use.

Ritonavir Half-Life

The half-life of ritonavir is approximately 3 to 5 hours. However, due to its role as a CYP3A4 inhibitor, the half-lives of other drugs metabolized by this enzyme can be significantly prolonged when co-administered with ritonavir. This pharmacokinetic interaction is a key reason ritonavir is used as a booster for other protease inhibitors.

Ritonavir Applications

Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older).

Ritonavir is a potent inhibitor of cytochrome P450 3A4 (CYP3A4). This inhibition allows ritonavir to boost the levels of co-administered drugs that are substrates of CYP3A4, particularly other protease inhibitors used in the treatment of HIV.

Reference:

  1. L. Morissette; S. Soukasene; D. Levinson; M. J. Cima; O. Almarsson (2003). “Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization”
  2. Hsieh, Yi-Ling; Ilevbare, Grace A.; Van Eerdenbrugh, Bernard; Box, Karl J.; Sanchez-Felix, Manuel Vincente; Taylor, Lynne S. (2012-05-12). “pH-Induced Precipitation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid State Properties”. Pharmaceutical Research. 29 (10): 2738–2753.
  3. Nieminen, Tuija H.; Hagelberg, Nora M.; Saari, Teijo I.; Neuvonen, Mikko; Neuvonen, Pertti J.; Laine, Kari; Olkkola, Klaus T. (2010). “Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir”. European Journal of Clinical Pharmacology. 66 (10): 977–985.
Related Products